Connect with us
DAPA Banner

Business

Southeast Asia’s RNAi Technology Market Poised for Rapid Expansion, Projected to Soar by 2033

Published

on

Southeast Asia's RNAi Technology Market Poised for Rapid Expansion, Projected to Soar by 2033

Southeast Asia is quietly emerging as one of the most dynamic frontiers in RNA interference (RNAi) biotechnology, as governments, academic institutions, and pharmaceutical companies converge on a technology once confined to Western research labs

Key takeaways

  • Southeast Asia’s RNAi technology market, valued at USD 80.20 million in 2024, is set to grow at a striking 16.25% CAGR through 2033, driven by rising government support and expanding pharmaceutical R&D investment across the region.
  • Singapore dominates the regional landscape, cementing its position as Asia’s premier precision medicine hub through landmark collaborations with global pharma giants including Alnylam, Bayer, Boehringer Ingelheim, and Novo Nordisk.
  • siRNA leads all RNAi modalities as the most commercially mature technology, with breakthrough research, such as NUS Medicine’s lipid nanoparticle therapy for liver disease, underscoring its growing clinical and commercial relevance across Southeast Asia.

 A new industry analysis covering the period through 2033 paints a striking picture of accelerating momentum, and the numbers are hard to ignore.

According to a comprehensive market report published by UnivDatos Market Insights, the Southeast Asia RNAi Technology Market was valued at approximately USD 80.20 million in 2024 and is projected to expand at a compound annual growth rate (CAGR) of roughly 16.25% through 2033. That trajectory, driven by a confluence of government policy, academic-industry collaboration, and surging demand for precision medicine, would place the region firmly on the global map for RNA-based therapeutics and research services.

What Is RNAi, and Why Does It Matter?

RNA interference is a gene-silencing mechanism that enables scientists to selectively suppress the activity of specific genes using short interfering molecules. In practical terms, it offers researchers a molecular scalpel: the ability to turn off disease-causing genes with extraordinary precision. Since its discovery earned a Nobel Prize in 2006, RNAi has moved steadily from the laboratory bench toward clinical application, finding use in drug discovery, rare disease treatment, oncology, and metabolic disorder research.

In Southeast Asia, the technology is gaining traction precisely because it shortens drug development timelines, reduces the cost of target validation, and integrates well with the outsourcing models increasingly favored by pharmaceutical companies seeking efficiency in a competitive global market.

Advertisement

siRNA Dominates the Market Landscape

Among the various RNAi modalities, which include short hairpin RNA (shRNA) and microRNA (miRNA), short interfering RNA, or siRNA, commands the largest share of the regional market. Its dominance reflects a straightforward reality: siRNA is the most clinically validated and commercially mature format, supported by established delivery systems and a proven track record in rare diseases, oncology, and metabolic conditions.

A noteworthy example of siRNA’s real-world potential emerged from Singapore in late 2025, when researchers at NUS Medicine announced a novel RNA-based therapy for metabolic dysfunction-associated steatohepatitis (MASH), a liver condition affecting approximately 25% of people globally and up to 40% of adults in Singapore. The team used lipid nanoparticles to deliver siRNA directly into liver cells, where it silenced a gene called SPTLC2 that drives the accumulation of ceramides, fat-like molecules linked to liver inflammation and fibrosis. The breakthrough illustrated exactly the kind of translational research driving long-term commercial demand for siRNA tools across the region.

Pharma and Biotech Companies Lead Adoption

On the end-user side, pharmaceutical and biotechnology companies represent the dominant segment. Their strategy is clear: use RNAi technology to de-risk drug targets before committing to expensive clinical investment, thereby improving development efficiency and pipeline diversity. Southeast Asia’s pharma companies are increasingly outsourcing RNAi-based discovery efforts, a trend that is catalyzing the growth of specialized service providers and contract development and manufacturing organizations (CDMOs) throughout the region.

A notable example of this dynamic came in April 2025, when GenScript Biotech Corporation, a global leader in biotechnology research services, announced a strategic partnership with NSG Bio, Singapore’s premier biotech incubator. Under the agreement, GenScript committed to offering preferential rates and expert technical guidance across its full range of biotech services to incubator residents, a direct investment in the kind of early-stage ecosystem that feeds long-term RNAi adoption.

Advertisement

Singapore: The Undisputed Regional Hub

If there is one country that defines Southeast Asia’s RNAi ambitions, it is Singapore. The city-state’s combination of world-class intellectual property protections, a proactive government, deep life-science infrastructure, and proximity to global pharmaceutical leaders has made it the region’s dominant commercialization hub for RNA technologies.

The most striking signal of Singapore’s position came in December 2025, when Precision Health Research, Singapore (PRECISE) announced a landmark collaboration with four global pharmaceutical giants, Alnylam, Bayer, Boehringer Ingelheim, and Novo Nordisk, under Phase II of Singapore’s National Precision Medicine (NPM) programme. The initiative marked Singapore as the first country in Asia to establish a pre-competitive collaboration with leading pharmaceutical companies, effectively setting the blueprint for how precision medicine ecosystems should be built in the region.

Thermo Fisher Scientific’s parallel investment reinforced the picture. In December 2025, the company announced an expansion of its bioprocessing capabilities across Asia, including a broadening of its existing Bioprocess Design Center in Singapore, offering bench-to-pilot scale bioprocessing, expert-led training, and technical collaboration to help companies scale early-stage processes toward sustainable biomanufacturing.

Vietnam: The Fastest-Growing Market to Watch

While Singapore commands today’s market, the report identifies Vietnam as the country expected to record the highest growth rate over the forecast period. Vietnam’s emergence reflects a broader pattern: as the biotech ecosystems of Indonesia, Thailand, the Philippines, and Malaysia continue to mature, RNAi adoption is spreading beyond the region’s established innovation hubs into markets characterized by rapidly improving lab infrastructure, growing research talent pipelines, and expanding government commitment to life sciences.

Advertisement

The Competitive Landscape

The Southeast Asia RNAi technology space features a mix of global giants and regional specialists. Key players operating in the market include GenScript, Integrated DNA Technologies (a Danaher Corporation subsidiary), Thermo Fisher Scientific, Merck KGaA, QIAGEN, Revvity, ABT Biomedical Solutions, and Bio Basic Asia Pacific. Their growth strategies span partnerships, new product launches, geographic expansions, and licensing agreements.

One example: in August 2025, Hongene Biotech Corporation, a CDMO focused on nucleic acid therapeutics, secured a non-exclusive licensing agreement with UMass Chan Medical School to produce and supply extended nucleic acid (exNA) monomers and modified oligonucleotides for research use. The deal expanded access to innovative oligonucleotide technologies for both academic and biopharmaceutical researchers working on RNAi, antisense oligonucleotides, CRISPR guides, and related modalities.

Challenges Ahead

The road to full regional maturity is not without obstacles. The report identifies limited local RNAi manufacturing capacity, the high cost of advanced tools, a shortage of specialists trained in RNA technologies, and uneven regulatory frameworks across countries as the principal headwinds. Regulatory complexity for RNA-based therapeutics remains particularly challenging: each Southeast Asian market brings its own approval pathways, complicating the commercialization strategies of companies seeking regional scale.

Uneven adoption is perhaps the most structural challenge. While Singapore and, increasingly, Malaysia and Vietnam are building the institutional and industrial scaffolding for serious RNAi development, other markets in the region are earlier in that journey. Bridging that gap will require sustained policy commitment, cross-border talent development, and deeper integration between academic research and commercial application.

Advertisement

The Bigger Picture

What the Southeast Asia RNAi market ultimately represents is a test of whether the region can convert scientific ambition into durable biotechnology competitiveness. The ingredients are increasingly in place: government support is growing, global companies are expanding their regional footprint, and breakthrough research, from Singapore’s liver disease therapy to the continent-wide precision medicine collaborations, is generating the kind of proof points that attract further investment.

At a 16.25% annual growth rate, the sector is expanding nearly twice as fast as the broader global healthcare market. For investors, researchers, and policymakers with a view toward the next decade of biomedical innovation, Southeast Asia’s RNAi story has only just begun

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Trade bodies say guaranteed hours under Employment Rights Act could threaten jobs

Published

on

Business Live

The British Retail Consortium, Food and Drink Federation, Recruitment and Employment Confederation, and UK Hospitality write to Government

A pint being poured

UK Hospitality signed the letter to Government(Image: PA)

Four trade bodies say proposals for guaranteed hours under the Employment Rights Act could threaten quality jobs.

Advertisement

The British Retail Consortium, Food and Drink Federation, Recruitment and Employment Confederation, and UK Hospitality jointly wrote to the Government warning that the measure could result in diminished opportunities and worse conditions for workers.

They put forward amendments to the policy which they believe would prevent “the double whammy of increasing unemployment and fewer young people entering the labour market”.

The letter stated: “Across our sectors, concern is deep and growing that the current approach risks stripping flexibility from the labour market at precisely the wrong moment.

“With demand already weakened, poorly designed guaranteed hours measures could become a tipping point, pushing employers to reduce hiring, limit hours or withdraw flexible roles altogether, denying work to those who need it most, or moving to less secure, more casual models of engagement.”

Advertisement

A Government spokesperson responded: “We will only achieve a thriving economy once people have a wage they can count on, which is why we’re giving greater certainty to over half the UK’s workforce through our Employment Rights Act.

“We will ensure people can have the security they need by giving eligible workers the right to guaranteed hours, and we will work closely with workers and employers on how the measures are implemented.”

Continue Reading

Business

SPDR infrastructure ETF to delist from Italian exchange

Published

on


SPDR infrastructure ETF to delist from Italian exchange

Continue Reading

Business

AI drives global IT spending to $6.31 trillion, but Indian IT firms face a margin squeeze, warns Gartner

Published

on

AI drives global IT spending to $6.31 trillion, but Indian IT firms face a margin squeeze, warns Gartner
Global IT spending has been revised sharply upward — from $6.15 trillion in February to $6.31 trillion in just two months — and the driver is almost entirely AI. That is the assessment of John-David Lovelock, Chief Forecaster at Gartner, who told ET Now that AI-optimised servers and hyperscaler data centre buildouts are adding significant sums to technology investment forecasts worldwide.

“We are building the foundation for what we need to run AI large language models and agents in the future,” Lovelock said, noting that enterprise networking equipment spending has also risen as a direct knock-on effect of the hyperscaler expansion.

India’s opportunity in managed services

Despite overall IT services growth running at a modest 3–4%, Lovelock sees a genuine opportunity opening up for India. As CIOs globally shift their internal teams away from routine, commoditised work toward strategic AI initiatives, a labour gap is emerging — and managed services providers are well placed to fill it.

Advertisement

The next phase of that opportunity, he said, lies in managed services providers building AI and agentic automation into their offerings, creating a new layer of cost efficiency for global clients. India, with its deep services talent base, is well positioned to capture this demand.

The uncomfortable reality for services firms

But Lovelock did not shy away from the structural challenge facing Indian IT. The industry is at a crossroads, he said — and the dynamics are unfavourable for pure services players compared to software companies.


When a software firm invests in AI, clients reward it with larger contracts for richer features. When a services firm does the same, clients expect the efficiency gains to be passed back to them in the form of lower prices. “Services firms spend money to bring in AI-enabled delivery and they are rewarded with smaller contracts,” Lovelock said plainly. That asymmetry is a structural headwind the entire global services industry — not just India — must navigate.

India does not need to win the data centre race

On the question of India’s participation in the AI infrastructure buildout, Lovelock offered a reassuring perspective. Unlike cloud computing, where data centres need to be close to end users due to latency constraints, AI delivery can tolerate the delay involved in distance. This means India does not need to match the United States — which accounts for over 50% of global AI spending — in mega data centre construction to remain relevant.Having local data centres would help India build its own large language models and domain-specific AI, but it is not a prerequisite for benefiting from and contributing to the global AI economy.

Advertisement

Margins under pressure near to mid-term

For IT companies broadly, Lovelock warned that margins will face significant pressure in the near to medium term. The industry is still in an investment phase — overbuilding data centre capacity ahead of demand — and many companies are offering AI products, services, and tokens at reduced prices or free to build user bases. A clear, standardised path to monetising that infrastructure has yet to emerge, and the means of doing so vary widely across companies.
The broader message: the AI era creates real opportunity for India’s IT sector, but the business model of services delivery is being fundamentally disrupted — and firms that do not embed AI into how they work, not just what they sell, risk being left behind.

Continue Reading

Business

Australia’s Two-Speed Housing Market Cools as Sydney, Melbourne Prices Slip in 2026

Published

on

McDonald's is the latest US organization to rethink its diversity practices following a Supreme Court ruling that reversed affirmitive action in university admissions

SYDNEY — Australia’s $12.6 trillion residential property market is showing clear signs of divergence and moderation in early 2026, with house prices falling in Sydney and Melbourne while resource-driven cities like Perth and Brisbane continue to post strong gains amid persistent supply shortages and shifting interest rate pressures.

The Sydney Opera House also switched its lights off to mark the event
Sydney
AFP / Steven Saphore

The latest data from Cotality released in April reveals national dwelling values rose a modest 0.7% in March, bringing first-quarter growth to 2.1%. While this marks continued appreciation, the pace has slowed noticeably from late 2025, reflecting higher borrowing costs, cost-of-living pressures and growing buyer caution in the country’s two largest markets.

Sydney home prices fell 0.2% over the first three months of the year, while Melbourne recorded a 0.6% decline. Together, these two cities — which account for roughly 55-60% of the national market — are exerting downward pressure on the broader index. Median house prices now stand at approximately $1.295 million in Sydney and $828,000 in Melbourne.

In contrast, Perth surged 7.3% in the March quarter, Brisbane rose 5.1%, Adelaide gained 3.6%, and smaller capitals like Darwin, Hobart and Canberra also posted positive growth. This “two-speed” dynamic has become a defining feature of the 2026 market, driven by differing economic conditions, migration patterns and housing supply levels across states.

Factors Driving the Split

Advertisement

Economists point to several key influences. Western Australia and Queensland continue to benefit from strong resources sectors, population inflows and relatively affordable entry points compared to the eastern seaboard. Perth’s median dwelling value is approaching $1 million after years of rapid appreciation, yet demand remains robust due to tight inventory.

Sydney and Melbourne, however, are feeling the pinch of higher interest rates and stretched affordability. The Reserve Bank of Australia’s rate settings have curbed borrowing capacity, particularly for buyers in premium segments. Lower-quartile properties in these cities have held up better, while higher-end homes have seen noticeable softening.

A federal first-home buyer scheme expansion has also contributed to price pressure at the lower end of the market. Cotality data shows eligible homes rose 6.7% in the six months following policy changes — nearly double the growth in higher-priced segments — raising concerns the initiative may be inflating entry-level prices rather than purely improving access.

National Outlook and Forecasts

Advertisement

Major banks and forecasters have moderated their 2026 predictions. Commonwealth Bank now expects national dwelling price growth of around 5% this year and 3% in 2027, down from previous estimates. ANZ forecasts capital city prices to rise 2.8% in 2026 and 2.1% in 2027, citing higher rates and affordability constraints.

Despite the cooling, fundamentals remain supportive in many areas. Record-low rental vacancy rates continue driving investor interest, while net overseas migration sustains demand. However, new housing supply is gradually increasing, which could help ease pressure later in the year and into 2027.

Rental Market Remains Tight

The rental sector shows little sign of relief. National median rents continue climbing, with some regional areas in South Australia seeing year-on-year increases of 12.5%. Vacancy rates hover near historic lows, exacerbating affordability challenges for tenants and adding fuel to political debates ahead of the federal budget.

Advertisement

Challenges and Policy Implications

Housing affordability remains a critical issue heading into the 2026 federal budget. Experts urge policymakers to prioritize boosting supply, protecting rental stock and removing barriers to downsizing rather than measures that could further inflate prices. Calls for tax reform, planning system overhauls and incentives for build-to-rent projects are growing louder.

First-home buyers face particular hurdles, with the national median property price hovering near $908,000-$933,000. Only about 30% of properties fall below $700,000, intensifying competition in the affordable segment.

Regional Variations Offer Opportunities

Advertisement

Buyers and investors are increasingly looking beyond the traditional east coast hotspots. Perth, Brisbane and Adelaide offer stronger growth prospects in the near term, though analysts warn that rapid gains could moderate as affordability constraints spread. Regional markets have also shown resilience, with some areas outperforming capitals due to lifestyle shifts and remote work trends.

What Lies Ahead

The Australian real estate market in 2026 is transitioning from the boom conditions of recent years to a more balanced — yet still challenging — environment. While national values continue inching higher overall, the widening city-by-city and segment-by-segment gaps suggest a period of selective growth rather than uniform appreciation.

Prospective buyers may find improved negotiating power in Sydney and Melbourne, particularly at the upper end, while investors seeking yield and growth potential are eyeing western and northern markets. For sellers, timing and pricing strategy will be crucial in a market that rewards realism over optimism.

Advertisement

As the year progresses, interest rate decisions, federal budget measures and global economic signals will play key roles in shaping the trajectory. For now, Australia’s housing market remains resilient but clearly cooling, offering both opportunities and risks for participants across the spectrum.

Continue Reading

Business

2 Injured in East Austin Outside Sam’s BBQ; Suspect Still at Large

Published

on

Austin Shooting: 2 Injured in East Austin Outside Sam's BBQ;

AUSTIN, Texas — Two people were shot and injured Sunday night outside the popular Sam’s BBQ restaurant in East Austin, prompting a large police response and leaving the suspect still at large Monday as detectives continue to interview witnesses and search the area.

Austin Shooting: 2 Injured in East Austin Outside Sam's BBQ;
Austin Shooting: 2 Injured in East Austin Outside Sam’s BBQ; Suspect Still at Large

Austin Police Department officers responded to multiple 911 calls reporting shots fired around 8:26 p.m. in the 2000 block of East 12th Street near Chicon Street. Upon arrival, they found two victims suffering from gunshot wounds outside the beloved East Austin barbecue landmark. Both were transported to area hospitals with non-life-threatening injuries.

No fatalities have been reported, and authorities described the incident as isolated with no immediate threat to the broader public. East 12th Street between Chicon and Alamo streets remained closed for several hours as crime scene investigators processed the area.

Busy Night in Vibrant Neighborhood

Advertisement

The shooting occurred in a bustling section of East Austin known for its food scene, nightlife and cultural vibrancy. Sam’s BBQ, a longtime neighborhood staple at 2000 E. 12th St., had been hosting events earlier in the day, and nearby businesses including the Austin Daiquiri Factory were active on a busy Sunday evening.

Witnesses described hearing multiple gunshots followed by chaos as people sought cover. Police have not released detailed descriptions of the victims or the suspect. Detectives are reviewing surveillance footage from the area and interviewing those present at the time of the incident.

The suspect fled the scene on foot, and no vehicle description or suspect sketch has been released. APD urged anyone with information to contact detectives or Austin Crime Stoppers. A reward for information leading to an arrest may be offered.

Community Reaction and Safety Concerns

Advertisement

East Austin residents expressed shock and frustration over yet another violent incident in the rapidly changing neighborhood. Longtime locals noted the area’s transformation from a historically working-class and minority community to a hub for new development, restaurants and nightlife. Some voiced concerns about rising crime amid gentrification pressures.

Sam’s BBQ owners and staff have not issued a public statement, but the restaurant is a beloved institution known for its smoked meats and community ties. The shooting’s proximity to the establishment has drawn extra attention from both patrons and local media.

Austin Police Chief has characterized the event as isolated and urged calm while the investigation proceeds. No connections to other recent incidents have been reported.

Broader Context of East Austin Violence

Advertisement

While Austin remains one of the safer major cities in Texas, sporadic shootings in East Austin have raised ongoing community discussions about public safety, policing strategies and socioeconomic factors. City leaders have invested in violence interruption programs and increased patrols in high-activity areas, but incidents like Sunday’s continue to test those efforts.

This latest shooting comes amid a busy weekend in the city, with various events drawing crowds to East Austin venues. Officials reminded residents to remain vigilant, especially during evening hours in entertainment districts.

Investigation Ongoing

Austin Police continue to gather evidence and seek tips from the public. Anyone with video footage, eyewitness accounts or other information is encouraged to contact APD or Crime Stoppers anonymously. Updates will be released as they become available.

Advertisement

The two victims are expected to survive, according to preliminary hospital reports, though their conditions were not detailed publicly. Family members have not been identified, and police are withholding names pending notification.

As East 12th Street reopens and the neighborhood returns to its usual rhythm, the search for the suspect remains active. Authorities emphasize that this appears to be a targeted or isolated dispute rather than a random act of violence, though the full motive has not been determined.

For now, the community around Sam’s BBQ and surrounding blocks is processing another instance of gun violence in a city that continues to grapple with growth, change and safety concerns. Police ask for patience as detectives work to bring the suspect into custody and provide answers to those affected.

Advertisement
Continue Reading

Business

Paytm shares crash 8% as RBI cancels Paytm Payments Bank’s banking license. What lies ahead?

Published

on

Paytm shares crash 8% as RBI cancels Paytm Payments Bank's banking license. What lies ahead?
The shares of One 97 Communications, the parent company of the popular fintech platform Paytm, crashed around 8% on Monday after the Reserve Bank of India (RBI) cancelled Paytm Payments Bank‘s (PPBL) banking licence, following which the company announced it will shut down the subsidiary.

In an exchange filing released after market hours on Friday, Paytm announced that the RBI has effectively cancelled Paytm Payments Bank’s banking licence. Paytm clarified that it does not have any exposure to the associate entity and provides no services in partnership with it. It added that Paytm Payments Bank operates independently.

“There is no direct financial impact on the company since, as previously disclosed, the company had already impaired its investment in PPBL as of March 31, 2024,” it added. “As informed earlier, Paytm (One 97 Communications Limited) and its services, which have been operating without interruption, will continue to operate uninterrupted. These include the Paytm app, Paytm UPI, Paytm Gold and all other services offered by its subsidiaries and associated companies, such as Paytm QR, Paytm Soundbox, Paytm Card Machines, Paytm Payment Gateway, Paytm Money, among others,” it further said.

This comes after more than two years of regulatory scrutiny and restrictions, including a ban on fresh deposits in 2024. Paytm had obtained a limited banking license in August 2015 that allowed it to take small deposits but not give out loans. The central bank said the bank’s operations were “detrimental” to depositors and public interest, citing compliance lapses, including issues around customer due diligence and governance. The general character of the management of the bank is prejudicial to the interest of depositors as also the public interest,” the statement said, adding “No useful ⁠purpose or ‌public interest would be served by allowing the bank to continue.”

Advertisement

Later on Saturday, Paytm announced that PPBL’s board of directors and shareholders have approved the necessary resolutions to enable the winding up of the company. “The company wishes to assure its shareholders and investors that the winding-up of PPBL and the consequential cessation of the associate relationship are not expected to have any material impact on the business, operations, or financial condition of the company. The company continues to operate its businesses independently and in accordance with applicable laws and regulations,” it added.


Sensex, Nifty today: Catch all the LIVE stock market action here

Bernstein on Paytm

RBI’s decision to cancel the banking license of Paytm Payments Bank is likely to be incrementally negative for its parent, Bernstein said in its note. The brokerage described the regulator’s language in its communication as “harsh” and “concerning.” That said, the Societe Generale Group-backed brokerage has retained an ‘Outperform’ rating on Paytm, with a target price of Rs 1,500, implying an upside of around 31% from the previous closing price.

“While Paytm has no role in the current management/board of PPBL (despite the 49% ownership), the harsh language in the RBI’s letter is concerning,” Bernstein said, noting the history of regulatory actions against the business.

“Post the RBI restrictions on Paytm Payments Bank Limited (PPBL) in early 2024, the company did put in time and effort to terminate the interlinkages between PPBL and the core business, reconstitute the board, and take steps to potentially revive operations of the bank,” the note said.

Advertisement

The brokerage sees no impact on current business or numbers as the operations of PPBL have been suspended for more than a year, and the company has created a clear separation between the payments bank and the parent company, especially after the regulatory action in early 2024.

Bernstein believes this development could clear the way for the company to apply for an NBFC or PPI license, which might enable Paytm to offer certain payment products (e.g., wallet) and credit products.

Goldman Sachs on Paytm

Goldman Sachs maintained its ‘Buy’ rating on Paytm shares, but reduced its target price to Rs 1,400 apiece from Rs 1,470. The latest target price implies an upside potential of nearly 31% from the stock’s previous closing price.

The international brokerage said it sees the RBI’s cancellation of the associate entity’s banking license as an incremental negative, although there is no direct financial impact on Paytm, ET Now reported. The key risk is the potential impact on customer or merchant sentiment, it said.

Advertisement

While this may act as a near-term overhang, Goldman Sachs added that the core business momentum of Paytm remains intact.

Bonanza Portfolio on Paytm

The cancellation of Paytm Payments Bank licence by Reserve Bank of India is fundamentally neutral for One97 Communications, as the investment had already been fully impaired and operational decoupling was completed in early 2024, said Abhinav Tiwari, Research Analyst at Bonanza. He added that this event largely formalizes the closure of a non core, non contributing entity rather than introducing a fresh financial shock.

“Operationally, the core business remains resilient, with payments GMV and merchant base showing healthy traction, alongside strong growth in financial services distribution. The company has delivered a visible turnaround with positive PAT and improving EBITDA margins, supported by a strong cash buffer. However, the investment case still relies on sustainability. Margins remain thin, ROE trajectory is yet to normalize, and past regulatory lapses continue to weigh on institutional confidence. Overall, while the regulatory overhang reduces, execution consistency over the next few quarters will be critical to justify re-rating,” he added.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Advertisement
Continue Reading

Business

ATOME to host investor presentation on Villeta project Tuesday

Published

on


ATOME to host investor presentation on Villeta project Tuesday

Continue Reading

Business

Tech and Financial Stocks Lead Modest Market Rebound

Published

on

Australia Housing Market 2026: Two-Speed Boom Persists as Prices Hit

SYDNEY — The S&P/ASX 200 index showed resilience Monday as select technology, financial and industrial stocks posted strong gains, with Data#3 Ltd, Suncorp Group and Austal Ltd emerging as the session’s standout performers amid broader market caution and mixed commodity prices.

ASX 200 Top Gainers: Telix Pharma Jumps 3.23% on FDA
ASX 200 Top Gainers Today: Tech and Financial Stocks Lead Modest Market Rebound

Data#3 Ltd (ASX: DTL) led the benchmark with a 5.81% surge to close at $8.01, driven by strong investor sentiment around its IT services growth outlook and positive sector rotation. Suncorp Group Ltd (ASX: SUN) followed closely, jumping 4.47% to $17.05 on expectations of solid insurance earnings, while shipbuilder Austal Ltd (ASX: ASB) climbed 4.29% to $4.62 after securing new defence contracts.

The top five gainers rounded out with Endeavour Group Ltd (ASX: EDV) up 3.55% to $3.50 and another financial or industrial name showing strength in defensive plays. While the ASX 200 closed only modestly higher overall, these movers highlighted selective buying in quality names despite geopolitical tensions and softer resource prices weighing on the broader index.

Market Context and Drivers

Monday’s trading occurred against a backdrop of cautious global sentiment. Wall Street futures pointed to modest gains overnight, but concerns over Middle East developments and fluctuating commodity prices kept Australian investors selective. The resources sector faced headwinds from softer iron ore and oil prices, while financials and technology attracted capital seeking stability and growth.

Advertisement

Data#3’s strong performance reflected ongoing digital transformation demand across Australian businesses. The company, a leading IT services provider, has consistently beaten earnings expectations, making it a favourite among fund managers seeking exposure to the technology sector without the volatility of pure software plays.

Suncorp benefited from positive analyst commentary on its general insurance division and expectations of steady premium growth amid rising reinsurance costs. The result underscores the defensive appeal of insurance stocks in an uncertain economic environment.

Austal’s gain came after announcements of expanded naval shipbuilding contracts, highlighting the strength of Australia’s defence industry amid regional security concerns. The company has positioned itself well for long-term government spending on naval capabilities.

Broader Market Performance

Advertisement

The ASX 200 closed with a modest gain, supported by these outperformers but capped by weakness in mining heavyweights. Materials and energy stocks generally lagged, reflecting softer commodity prices. Banking stocks showed mixed results, with some benefiting from yield-seeking flows.

Trading volume remained moderate, typical for a Monday session. Institutional investors appeared to rotate into quality names with strong balance sheets and clear growth narratives, a pattern seen repeatedly in 2026’s choppy market conditions.

What This Means for Investors

Monday’s top gainers illustrate the importance of stock-specific stories over broad market direction. In a two-speed economy where Sydney and Melbourne housing markets cool while resource states boom, investors are rewarding companies with resilient earnings and clear catalysts.

Advertisement

Analysts recommend focusing on businesses with pricing power, strong balance sheets and exposure to structural growth themes such as digitalisation, defence and financial services. Data#3, Suncorp and Austal exemplify these traits, explaining their outperformance.

Looking Ahead

This week brings key domestic data releases, including inflation figures that could influence Reserve Bank of Australia expectations. Global cues from earnings seasons in the US and ongoing geopolitical developments will also shape sentiment. Investors should watch for continued rotation between defensive and cyclical sectors.

The ASX 200’s modest rebound on selective strength suggests underlying resilience despite headline volatility. For those positioned in quality names like today’s top gainers, the market continues to reward patience and fundamental focus. As always, diversification across sectors remains key in Australia’s uniquely resource-influenced equity market.

Advertisement
Continue Reading

Business

Smarter Web Company names Oliver Hewett financial controller

Published

on


Smarter Web Company names Oliver Hewett financial controller

Continue Reading

Business

Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisition

Published

on

Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisition
Shares of Sun Pharmaceutical Industries gained as much as 4.2% to their day’s high of Rs 1,688 on the NSE on Monday after the company announced the acquisition of Organon & Co. for an enterprise value of $11.75 billion, acquiring all outstanding shares of the overseas pharma company at $14 per share in cash.

The Economic Times was the first to report earlier this year that Mumbai-based Sun Pharma was closing in on the $12 billion acquisition of Organon, a debt-ridden US company specialising in women’s health that was spun off from MSD (Merck Sharp & Dohme) in 2021.

Sun Pharma’s acquisition of Organon

In an exchange filing released today, Sun Pharma said it has entered into a definitive agreement with Organon, which it called a global leader in women’s health with a portfolio spanning across 70 products and biosimilars commercialised across 140 countries, with US, Europe, China, Canada, and Brazil among its largest market. The US-based company has six manufacturing facilities across the European Union and emerging markets.

Advertisement

Sun Pharma plans to fund the acquisition through a combination of available cash resources and committed financing from banks. The transaction will be effected by a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger, it added. The said transaction is expected to close in early 2027, subject to customary conditions.

“The proposed acquisition of Organon is aligned with Sun Pharma’s strategy of growing its innovative medicines business. The combined company becomes a stronger player in established brands/branded generics business. The deal also enables Sun Pharma’s entry into biosimilars as a top-10 global player. Organon’s portfolio, global footprint and strong stakeholder relationships shall complement Sun Pharma’s existing strengths and enhance long‑term value creation,” Sun Pharma said.


After the completion of the acquisition of 100% stake, Sun Pharma will become one of the top 25 global pharmaceutical companies with combined revenue of $12.4 billion, a more innovative medicines focussed company with 27% revenue share, one of the top 3 companies in global women’s health category and the seventh largest global biosimilar player, the pharma giant said.
Also read | ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till date

What the management says

The transaction has been approved by the boards of both the companies, but is subject to customary closing conditions. Speaking about the acquisition, Sun Pharma Executive Chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform. We have deep respect for Organon’s mission and look forward to building on its legacy while driving sustainable long‑term growth.”

This transaction is a logical next step in strengthening Sun Pharma’s global business, said the company’s managing director Kirti Ganorkar. “Together, we will become a partner of choice for acquiring and launching new products. Our immediate priorities will be business continuity, disciplined integration and responsible value creation. We see strong potential in leveraging Organon’s talent pool. In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years,” Ganorkar added.

Advertisement

Organon’s Executive Chair Carrie Cox meanwhile said that the US-based company’s board determined that this all‑cash transaction offers compelling and immediate value to Organon stockholders. “We believe Sun Pharma is well positioned to support Organon’s businesses, employees and patients globally, and to further advance our commitment to delivering impactful medicines and solutions,” he added.

Also read | Sensex, Nifty today: Catch all the LIVE stock market action here

Sun Pharma share price

Notably, Sun Pharma shares tumbled around 10% in one month amid buzz over the bulky acquisition. Organon inherited $9.5 billion of debt during the MSD spinoff and has been facing intense competitive pressure from global drugmakers as well generic suppliers in all three of its broad business segments–women’s health, biosimilars and the established products range, which includes cardiovascular drugs, respiratory and non-opioid pain, bone health and dermatology drugs.

The latest data show Organon reduced debt to $8 billion in calendar 2025. In comparison, Sun has about $3.2 billion (Rs 26,000 crore) of net cash on its balance sheet. The management has said it’s willing to utilise this to fund large acquisitions. In FY26, Sun Pharma clocked sales of Rs 52,000 crore, the US and India contributed almost an equal share of 31-33%. The rest is divided between other markets and active pharmaceutical ingredients (APIs).

Advertisement

Last year, Sun Pharma acquired Checkpoint Therapeutics for $355 million upfront, and the deal value reached $416 million. This gave Sun Pharma access to Unloxcyt, an anti-cancer drug. Sales from 11 of its innovative drugs grossed $1.21 billion in the US. Those include ophthalmology, hair loss, dermatology and anti-cancer drugs. Sun Pharma’s largest innovative drug in the US is Ilumya, for the treatment of plaque psoriasis, which saw sales of $681 million last year.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Continue Reading

Trending

Copyright © 2025